HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Zhou, H. Articles by Everitt, D. E. Search for Related Content PubMed PubMed Citation Articles by Zhou, H. Articles by Everitt, D. E. Social Bookmarking                   What's this?

Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF- Monoclonal Antibody, in Subjects With Rheumatoid Arthritis

From Centocor Research and Development, Inc, Malvern, Pennsylvania (Dr Zhou, Dr Jang, Dr Bouman-Thio, Dr Xu, Dr Marini, Dr Pendley, Q. Jiao, Dr Shankar, S. J. Marciniak, Dr Rahman, Dr Baker, Dr Mascelli, Dr Davis, Dr Everitt) and Radiant Research, Dallas, Texas (Dr Fleischmann, Dr Cohen).

Golimumab is a fully human antitumor necrosis factor alpha (TNF-) monoclonal antibody that is being developed for intravenous and subcutaneous administration. To assess the pharmacokinetics and safety of the intravenous formulation of golimumab, 36 adult subjects with rheumatoid arthritis were randomly assigned to receive a single infusion of placebo or golimumab (0.1, 0.3, 1, 3, 6, or 10 mg/kg). Serum concentrations of golimumab were determined using a validated enzyme-linked immunosorbent assay method. In addition to the noncompartmental analysis and compartmental modeling, a population pharmacokinetics analysis using NONMEM was also conducted. Both the maximum serum concentration and the area under the serum concentrationtime curve appeared to increase in a dose-proportional manner. The median half-life ranged from 7 to 20 days. A 2-compartment population pharmacokinetic model adequately described the pharmacokinetics of golimumab. The following pharmacokinetic parameters (typical value [% coefficient of variation]) were estimated from the population pharmacokinetic model: clearance (CL: 0.40 [10.1%] L/d), volume of distribution in the central compartment (V_c: 3.07 [6.4%] L), intercompartmental clearance (Q: 0.42 [15.5%] L/d), and volume of distribution in the peripheral compartment (V_p: 3.68 [11.8%] L). Interindividual variability of the pharmacokinetic parameters was quantified for CL (44.3%), V_c (25.5%), Q (44.6%), and V_p (44.6%). Residual variability was estimated to be 15.0%. Body weight was found to be an important covariate on V_c. Golimumab was generally well tolerated. The pharmacokinetics of golimumab appeared to be linear over the dose range evaluated in this study.

Key Words: rheumatoid arthritis • human anti-TNF- monoclonal antibody (mAb) • golimumab • pharmacokinetics

Address for reprints: Address for correspondence: Honghui Zhou, PhD, FCP, Clinical Pharmacology & Experimental Medicine, Centocor Research & Development, 200 Great Valley Parkway, Malvern, PA 19355; e-mail: hzhou2{at}cntus.jnj.com.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. E. Wenzel, P. J. Barnes, E. R. Bleecker, J. Bousquet, W. Busse, S.-E. Dahlen, S. T. Holgate, D. A. Meyers, K. F. Rabe, A. Antczak, et al. A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-{alpha} Blockade in Severe Persistent Asthma Am. J. Respir. Crit. Care Med., April 1, 2009; 179(7): 549 - 558. [Abstract] [Full Text] [PDF]

				Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson, W. Xu, H. M. Davis, and H. Zhou Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis J. Clin. Pharmacol., June 1, 2008; 48(6): 681 - 695. [Abstract] [Full Text] [PDF]